ONCAlert | 2018 ASCO Annual Meeting

Gastrointestinal Cancers MORE >>

Atezolizumab (Tecentriq) has been granted a breakthrough therapy designation by the FDA for use in combination with bevacizumab (Avastin) as a first-line treatment for patients with advanced or metastatic hepatocellular carcinoma.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.